11:45 AM EDT, 04/28/2025 (MT Newswires) -- Guardant Health ( GH ) said Monday it launched its its molecular profiling test Guardant360 Tissue, which provides "a more complete view of cancer."

The tumor tissue test incorporates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data, the company said.

The test is covered by Medicare for eligible patients, the company said.

Price: 47.75, Change: -0.55, Percent Change: -1.14